Dipeptide variants of alafosfalin (L-alanyl-L-1-aminoethylphosphonic acid) with substantial differences in potency and antibacterial spectrum in vitro and in vivo have been synthesized. Certain dipeptides with alternptives to the L-alanyl residue had broader antibacterial spectra; activity against Pseudomonas aeruginosa was included. Some compounds had better in vivo activity than alafosfalin when introduced into infected rodents orally, but for the majority of the more active phosphonodipeptides, parenteral administration was more effective. Certain oligopeptides derived from the more active phosphonodipeptides possessed good in vitro activity against an extended range of organisms; they included Haemophilus influenzae, Streptococcus faecalis, and Streptococcus pneumoniae. The in vivo activity of some of these phosphono-oligopeptides was significantly greater than that of the parent dipeptide and correlated well with the in vitro results. This indicates that phosphono-oligopeptides exert part of their in vivo action directly, in addition to that arising from smaller peptides produced by peptidase cleavage.
Dipeptide variants of alafosfalin (L-alanyl-L-1-aminoethylphosphonic acid) with substantial differences in potency and antibacterial spectrum in vitro and in vivo have been synthesized. Certain dipeptides with alternptives to the L-alanyl residue had broader antibacterial spectra; activity against Pseudomonas aeruginosa was included. Some compounds had better in vivo activity than alafosfalin when introduced into infected rodents orally, but for the majority of the more active phosphonodipeptides, parenteral administration was more effective. Certain oligopeptides derived from the more active phosphonodipeptides possessed good in vitro activity against an extended range of organisms; they included Haemophilus influenzae, Streptococcus faecalis, and Streptococcus pneumoniae. The in vivo activity of some of these phosphono-oligopeptides was significantly greater than that of the parent dipeptide and correlated well with the in vitro results. This indicates that phosphono-oligopeptides exert part of their in vivo action directly, in addition to that arising from smaller peptides produced by peptidase cleavage.
Phosphonopeptides constitute a class of synthetic antibacterial peptide mimetics in which the C-terminal carboxyl group has been replaced by a phosphoryl [P(O) (OH)2] function (1) . These compounds are transported into bacteria by means of peptide permeases located in the bacterial cytoplasmic membrane. Within the cell they are cleaved enzymatically to liberate an aminoalkylphosphonic acid moiety which inhibits cell wall biosynthesis (3) . In a previous study, phosphonopeptides containing L-amino acids linked to the L-1-aminoethylphosphonic acid Ala(P) [ or less significantly, to aminomethylphosphonic acid, Gly(P)] as the acid terminal substituent were shown to forin the most interesting series of compounds (4) . On the basis of antibacterial activity in vitro and in vivo and stability to mammalian peptide hydrolase enzymes, alafosfalin [L-alanyl-L-1-aminoethylphosphonic acid; Ala-Ala(P)] was selected for detailed evaluation (1) (2) (3) (4) . (All amino acids and amino acid mimetics in this paper are of the L series, and L-is therefore omitted in abbreviations.)
Although alafosfalin had high levels of activity against certain members of the Enterobacteriaceae, including Enterobacter sp., Escherichia coli, Klebsiella sp., and Shigella sp., the antibacterial activity against Proteus and Pseudomonas spp. or streptococci (with the exception of Streptococcus faecalis) was modest (1, 2, 4) .
However, as the investigation of the mechanism of action of this new class of antibacterial agents developed, it appeared likely that phosphonopeptides with advantages over alafosfalin might be identified. This has been confirmed.
In our preliminary studies (4) we observed that certain phosphonodipeptides with different natural amino acids combined with Ala(P) showed very substantial differences in antibacterial activity. A detailed investigation of L-methionyl (Met)-Ala(P) established that the enhanced activity and broader antibacterial spectrum of this compound could be explained by more rapid transport into the bacteria than in the case of alafosfalin. Met-Ala(P) has not been developed further because it is more rapidly degraded by mammalian peptidases and is therefore less active in vivo than alafosfalin. This observation relating to Met-Ala(P) encouraged the examination of a wider range of dipeptides with the purpose of identifying phosphonopeptides with improved transport characteristics which retained, however, sufficient stability to mammalian peptidases to ensure good levels of antibacterial activity in vivo. The earlier studies (4) had also established that phosphono-oligopeptides displayed differences in their antibacterial spectrum in vitro from the corresponding phosphonodipeptides.
In this paper we describe investigations directed toward identifying novel phosphonopeptides with enhanced antibacterial activity both in vitro and in vivo. 
MATERIALS AND METHODS
Amino acid and peptide mimetics. The term amino acid mimetic as used in this paper refers to synthetic variants of conventional a-amino acids with the carboxyl group replaced by alternative acidic functions, usually the phosphoryl [P(O) (OH)2] group. Peptide mimetics incorporate residues of these amino acid mimetics.
Synthesis of phosphonopeptides. The phosphonopeptides described in this report were synthesized by the methods described previously (4) .
Chemical characteristics of the new compounds described in this paper are as shown in Table 1 Determination of MIC. Minimum inhibitory concentrations (MICs) were determined by an agar incorporation method as described previously (4), but using final concentrations of agents ranging from 0.007 to 128,Ug/ml. The defined susceptibility medium, free from antagonists to small peptide mimetics, reported in the previous communication (4) was used throughout these studies, except for the results shown in Table  8 The media were sterilized at 121°C for 15 min. When testing S. pyogenes and S. pneumoniae on agar, 7% defibrinated horse blood or 7% "chocolate" horse blood (for H. influenzae) was added. In broth culture studies, the addition of 5% horse serum was necessary for the streptococci, and a further addition of 2 ml/ liter of a saturated solution of hemin in 0.5% ammonia (prefiltered on a GF/C filter to remove undissolved hemin, then filter sterilized) was necessary for H. influenzae.
Intracellular concentration of Ala(P) in bacteria. Unless otherwise stated, cell suspensions (50 ml; 3 x 108 bacteria per ml; late exponential phase) were incubated with 100 yM phosphonopeptide in the defined susceptibility medium (4) at 37°C for 15 min. The cells were harvested by centrifugation, washed with 0.9% (wt/vol) NaCl at 20°C, and suspended in 5 ml of water. The cell contents were extracted by heating to 100°C for 5 min, and 0.8-ml samples of the extract supernatant were analyzed with a JEOL amino acid analyzer as previously described (3) .
Intercellular concentrations of Ala(P) were calculated from peak areas and corrected for an intracellular volume of 2.7 pl/mg (dry weight) of cells (16) .
Transport studies with S. pneumoniae and S. pyogenes were carried out with the modifications described in the legend to Fig. 3 .
In vivo activity. In vivo activity was studied in a mouse septicemia model by using groups of five female CFW or MF1 mice (17 to 19 g) infected intraperitoneally with 1.0-ml suspensions of overnight broth cultures diluted in mucin (2.5% [wt/vol] final concentration) to yield four to eight times the 99% lethal dose. Compounds were administered subcutaneously or orally at 1, 3, and 5 h postinfection in twofold dose steps as solutions freshly prepared in sterile physiological saline. The number of mice surviving for 7 days was used to calculate the 50% curative dose by the method of Weil (14) . Each experiment included at least 20 infected, untreated control animals, which usually died within 48 h. Surviving animals were not examined for persisting bacteria, but experiments were rejected if more than 10% of the untreated infected controls survived for 7 days.
.RSTJLTS Antibacterial activity of phosphonodipeptides in vitro. In our earlier publications (1, 2, 4), the antibacterial activities of selected phosphonodipeptides in the series X-Ala(P) (X = L-anmino acid) were reported. Further analogs have now been synthesized (Table 2) to extend this series to include the majority of the natural L-amino acids. Several compounds had greater antibacterial potency than alafosfalin. Like MetAla(P), which was reported previously, the Arg, Asp, Cit, a-Glu, and Leu analogs were weakly [a]DD20b
Phosphonodipeptides: X-L-Ala(P) active against P. mirabilis (Table 2) . How ever, certain phosphonodipeptides containing branched-chain amino acids such as Ile (Table  2) or Val (4) were less potent antibacterial agents than alafosfalin.
As the Leu and Met analogs of X-Ala(P) had particularly interesting in vitro antibacterial properties, a series of compounds containing straight-chain aliphatic amino acids (X = L-H2N-CH[(CH2)nH]-CO-[n = 0-8]) was synthesized. Optimum activity (Table 3) was observed with n = 3 and 4, i.e., Nva-Ala(P) and MeAla(P); this included moderate levels against Pseudomonas aeruginosa (MICs, 32 and 64 jig/ ml, respectively) ( Table 3) . Moreover, the Abu (n = 2) and Ahe (n = 5) analogs possessed similarly high levels of antibacterial activity, but were not active against P. aeruginosa (MIC, >128 yg/ml). Decreased activity was generally observed against most organisms with AdeAla(P) (n = 8), but for S. typhimurium or P. mirabilis this compound was as active as NvaAla(P) ( Table 3) .
Transport of phosphonodipeptides by bacteria. Phosphonodipeptides derived from the straight-chain aliphatic amino acids that were investigated delivered Ala(P) more effectively than alafosfalin into bacteria ( Fig. 1) and were more potent. For the most part, there was a good correlation between the antibacterial potency of phosphonodipeptides and the rate of release of Ala(P) within the bacteria. The results for E. coli NCIB 8879 after treatment with various phosphonodipeptides are summarized in Fig. 2 . In general, MICs were inversely proportional to the concentration of Ala(P) delivered, but His-Ala(P), Gly-Ala(P), and Val-Ala(P) were exceptions; in these cases another factor appears to be involved in the mechanism of action.
There was also a correlation between antibacterial activity and the rate of phosphonodipeptide transport in other organisms. In P. mirabilis, the intracellular liberation of Ala(P) from Arg-Ala(P), a-Glu-Ala(P), and Met-Ala(P) (analogs that have MICs of <128 ,ig/ml against this organism) was significantly higher than that from the less active analog, alafosfalin ( Table 4) . The a-Glu analog and phosphonodipeptides with aromatic amino acid residues were poorly transported by P. aeruginosa (Table 4) ; all were inactive (MIC, >128,ug/ml).
In the series of phosphonodipeptides XAla(P) in which X = L-H2N-CH[(CH2)nH]-CO-, the rate of transport and subsequent Ala(P) liberation in P. mirabilis and Serratia marcescens occurred most rapidly at n = 2 to 8 ( Fig. 1) . Overall, there was a good correlation between transport parameters (Fig. 1 ) and antibacterial activity (Table 3 ). In vivo antibacterial activity of phosphonodipeptides in the X-Ala(P) series. The in vivo antibacterial activities of representative phosphonodipeptides for oral and parenteral administration in an E. coli mouse septicemia model are summarized in Tables 5 and 6 . ArgAla(P) was the only compound with considerably greater activity than alafosfalin when given by both routes. Nva-Ala(P) and, to a lesser extent, some related phosphonodipeptides were more active than alafosfalin when administered parenterally, but not when administered by the oral route.
Antibacterial activity of phosphono-oligopeptides in vitro. The earlier studies (4) established that phosphonotri-to hexapeptides had antibacterial properties in vitro that differed from related phosphonodipeptides with respect to both spectrum and potency. However, these differences were not expressed in vivo; in this case the potency aind spectrum resembled those of the corresponding dipeptide, produced, presumably, by the action of mammalian peptidases. Consequently, oligopeptides with N-terminal sarcosyl, pyroglutamyl, and branchedchain amino acid residues such as valyl were investigated in vivo to determine their potential for longer life. Several phosphonotetrapeptides with N-terminal sarcosyl residues had high levels of activity against H. influenzae and S. faecalis in vitro (Table 7) in addition to the organisms that were sensitive to the related phosphonodipeptides (Tables 2 and 3 ). Replacement of this sarcosyl by pyroglutamyl, N-allylglycyl, or N-n-propylglycyl did not improve potency or spectrum. In general, related phosphonotetra-and pentapeptides have similar antibacterial properties in vitro (Table 7) .
Unlike phosphonodi-and tripeptides, the corresponding tetra-and higher phosphono-oligopeptides that were investigated were active in vitro against S. pneumoniae and S. pyogenes, major gram-positive respiratory tract pathogens ( Fig. 3 and Table 8 ). Moreover, it was found for S. pneumoniae, but not S. pyogenes (Table 8) , that oligopeptides incorporating Nva-Ala(P) were more active than corresponding com- Percentage Ala(P) delivery relative to Alafosfalin FIG. 2. Relative intracellular delivery of Ala(P) and antibacterial action against E. coli NCIB 8879 for alafosfalin and a range ofphosphonodipeptides. Antibacterial activity and intracellular Ala(P) levels arising from the dipeptides X-Ala(P) were determined as described in the text. Ala(P) levels are expressed as a percentage of that arising from the phosphonodipeptide alafosfalin [Ala-Ala(P)]. Lys, lysyl; Phe, phenylalanyl; Pro, prolyl. pounds with alafosfalin residues; this may be attributed to the known limitation of this organism in cleavages of alanyl peptides (7) ( Table  9 ). The phosphono-oligopeptides were, in general, more active against H. influenzae and S. faecalis than were the related phosphonodipeptides (Tables 7 and 8 high in vivo activity approaching that of NvaAla(P) against a typical E. coli infection. Moreover, they were more active than the corresponding phosphonodipeptide against S. faecalis in the mouse septicemia model (Table 10) . This indicated that the activity of the oligopeptide was not due alone to the dipeptide produced by peptidase cleavage in vivo. In the case of S. pyogenes (Table 10) potency was low and somewhat variable, whereas the phosphonodipeptide series had no action against this organism. S. pneumoniae was susceptible to certain phosphono-oligopeptides; strains 6431 and 6432 were inhibited by Sar-Nva-Nva-Ala(P) and pyroglutamyl (<Glu)-Nva-Nva-Ala(P) (50% curative doses for parenteral administration, 86 mg/kg and 67 mg/kg, respectively; we are indebted to R. Cleeland, Research Division, Hoffmann-La Roche, Inc., Nutley, N.J., for these results).
DISCUSSION
The investigations which were described in our earlier publications (1, 3) provided evidence to suggest that the action of phosphonopeptides on bacteria in vitro took place in three stages: (i) active transport from the medium into the bacterial cell, facilitated by cytoplasmic membrane permeases; (ii) intracellular cleavage to release the alanine mimetic, Ala(P); and (iii) interference with cell wall biosynthesis by the alanine mimetic through inhibition of alanine racemase and of uridine diphosphate-N-acetylmuramyl-alanine synthetase.
The variation in potency of various phosphon- Y, X, and n are as defined in Table 7 . b Determined as described in the text after incubation of S. pneumoniae NCTC 7465 at a cell density of 2.6 x i09 bacteria per ml with 100 uM phosphonopeptide for 60 min in defined medium (4) plus 2.5% (vol/vol) horse serum.
c The concentration of intact phosphonopeptides with N-alkylated N-terminal amino acids has not been taken into account in these calculations. Table   7 .
b MeVal, N-Methylvalyl.
opeptides in vitro may be attributed to differences in their action on different bacteria at one or more of these stages. It has become clear from our investigations (1, 3, 4) and from the work of others (8) (9) (10) (11) (12) ) that active transport of peptides into bacteria varies greatly with the organism and the composition of the peptides. This largely accounts for the differences in potency observed with phosphonopeptides. In the case of E. coli NCIB 8879, Fig.  2 summarizes data for 20 phosphonodipeptides. The cases of Gly-Ala(P), His-Ala(P), and ValAla(P) are exceptional in that the potency is greater than expected from the intracellular concentration of Ala(P) observed. Although these instances have not been studied further in detail, the result could be explained by a significant difference from alafosfalin in the rate of intracellular cleavage of these dipeptide mimetics.
The incorporation of unnatural amino acid residues with various lengths of aliphatic side chain into phosphonodipeptides was investigated after the observation that high antibacterial activity was associated with Met-Ala(P) and Leu-Ala(P). Again, high intracellular delivery of Ala(P) accounted for the antibacterial potency; there was no indication that the a-amino carboxylic acid itself was contributing significantly to the antibacterial activity. Although some antibacterial action through a surface-active effect occurs with compounds such as lauryl sulfate (5), the fact that Ade-Ala(P) had antibacterial activity equivalent to that of Nva-Ala(P) against P. mirabilis and comparable activity against other organisms (Table 3) suggested that this was not relevant to the case of phosphonodipeptides.
Phosphonodipeptides were only transported slowly by P. aeruginosa. This may reflect a strict structural requirement of the peptide permeases of this organism or, alternatively, the poor penetration of the outer membrane which has been observed for many compounds, including f-lactam antibiotics (13, 15) . In the case of Nva-Ala(P), which inhibited the growth of P. aeruginosa NCIB 8295 (MIC, 32 ,tg/ml), the rate of transport and intracellular Ala(P) delivery accounted for the observed activity.
It was apparent from this and our earlier studies that phosphono-oligopeptides displayed significant differences in in vitro activity from related phosphonodipeptides. S. pneumoniae and S. pyogenes are nonsusceptible to the dipeptides, but oligopeptides with four or more residues, which are transported by these bacteria, inhibit these organisms ( Fig. 3 and Table 8 ). It is interesting that the ability of certain natural oligopeptides to display strepogenin activity (17) and growth-promoting properties (18) for streptococci may well reflect the active transport of such peptides by permeases.
The phosphono-oligopeptides that were investigated for antibacterial activity against a range of organisms (Table 7) , including important respiratory tract pathogens (Table 8) , included compounds with N-terminal residues such as sarcosyl and pyroglutamyl which were intended to facilitate their use as in vivo agents. Although there was some reduction in antibacterial potency when these residues were incorporated rather than those of simple a-amino carboxylic acids, good levels of activity against many species were retained. The investigation in vivo confirned that compounds such as Sar-NvaNva-Ala(P) had interesting potential as in vivo antibacterial agents (Table 10 ).
In conclusion, these investigations have identified novel phosphonodipeptides and oligopeptides with interesting antibacterial activity in vivo. On the basis of this evidence, some of these compounds offer prospects for therapeutic use, either alone or in combination with other antibacterial agents that inhibit cell wall biosynthesis. Our studies on synergism with f8-lactam antibiotics will be reported shortly.
